Kringle Pharma, Inc.
JPX: 4884.T0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Tokyo Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kiichi Adachi
- Employees
- 15
- Headquarters
- Ibaraki, Japan
- IPO year
- 2020
- Market cap
- ¥3.3B
- Website
- https://www.kringle-pharma.com
Loading 4884…
Loading profile data…Frequently asked questions about 4884
What does Kringle Pharma, Inc. (4884.T) do?
Kringle Pharma, Inc. engages in the research and development, manufactures, and sells hepatocyte growth factor (HGF) protein pharmaceuticals for regenerative medicines. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury. Kringle Pharma, Inc. was...
Where does 4884.T trade?
Kringle Pharma, Inc. (4884.T) trades on the Tokyo Stock Exchange.
What sector is 4884.T in?
Kringle Pharma, Inc. (4884.T) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Kringle Pharma, Inc.?
Kiichi Adachi is the chief executive officer of Kringle Pharma, Inc. (4884.T).
Where is Kringle Pharma, Inc. headquartered?
Kringle Pharma, Inc. is headquartered in Japan.
Does 4884.T pay a dividend?
Kringle Pharma, Inc. (4884.T) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 4884.T go public?
Kringle Pharma, Inc. (4884.T) completed its initial public offering in 2020.